血栓烷合成酶抑制剂治疗急性脑梗死的疗效观察  

Clinical Observation on Therapeutic Effect of Thromboxane Synthetase Inhibitor in Acute Cerebral Infarction

作　　者：曲长海 曲方[2] 张广生[2] 

机构地区：[1]辽宁省本溪县第三人民医院,进修医师本溪117104 [2]沈阳军区总医院神经内科,沈阳110016

出　　处：《中国医药导刊》2008年第2期248-249,257,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:观察血栓烷合成酶抑制剂齐铭雷奥治疗急性脑梗塞的疗效和不良反应。方法:62例ACI患者分为治疗组30例和对照组32例。治疗组静脉滴注齐铭雷奥80mg,2次/日;对照组静滴刺五加60ml,1次/日;疗程均为14天。结果:治疗组总有效率93.3%,明显高于对照组的65.3%(P<0.01)。治疗组血小板聚集率、神经功能缺损程度评分和Barthel日常生活能力指数改变亦均优于对照组(均P<0.01)。结论:齐铭雷奥可以作为治疗急性脑梗塞的有效药物,为错过了发病早期溶栓最佳时机的患者提供一个新的治疗方法。Objective： To observe clinical therapeutic effect and adverse reaction of thromboxane synthetase inhibitor Ozagrel Sodium in acute cerebral infarction. Methods： 62 patients with acute cerebral infarction were randomly divided into treated group （n = 30） and the control group （n =32） Ozagrel Sodium in treating the treated group patients 80 mg i. v. gtt. B. i. d manyprickle acanthopanax root in treating the control group patients： 60 ml i. v. gtt. q. d. The course was 14 day. Results： The total effective rate in the treated group and the control group was 93. 3% and 65.3% respectively, and showed significant difference （P 〈 0. 01 ）. Blood platelet concentrate rate, the clinical defection degree of nerve function （CDDNF） and Barthel daily life ability index （BDLAI） were better in treated group patients then in control group ones （ P 〈 0. 01 ）. Conclusion： Ozagrel Sodium was a effective medicine and a new treatment method in patients that had lost the initial stage throm, bolysis chance in acute cerebral infarction.

关 键 词：急性脑梗塞 血栓烷合成酶抑制剂 

分 类 号：R743.3[医药卫生—神经病学与精神病学]